Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 2637418, 21 pages
https://doi.org/10.1155/2018/2637418
Review Article

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

1Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2Department of Endocrinology, Hospital de Braga, 4710-243 Braga, Portugal
3Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
4I3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal

Correspondence should be addressed to Laura Ribeiro; tp.pu.dem@oriebirl

Received 5 June 2017; Revised 28 September 2017; Accepted 11 October 2017; Published 17 January 2018

Academic Editor: Sabrina Corbetta

Copyright © 2018 Sofia Dias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Grundy, “Inflammation, hypertension, and the metabolic syndrome,” JAMA, vol. 290, no. 22, pp. 3000–3002, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Mehra, “Global public health problem of sudden cardiac death,” Journal of Electrocardiology, vol. 40, no. 6, pp. S118–S122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Romacho, M. Elsen, D. Rohrborn, and J. Eckel, “Adipose tissue and its role in organ crosstalk,” Acta Physiologica, vol. 210, no. 4, pp. 733–753, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. R. H. Stimson, J. Andersson, R. Andrew et al., “Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans,” Diabetes, vol. 58, no. 1, pp. 46–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Wolf, D. Wolf, H. Rumpold, B. Enrich, and H. Tilg, “Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes,” Biochemical and Biophysical Research Communications, vol. 323, no. 2, pp. 630–635, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Yamaguchi, J. G. Argueta, Y. Masuhiro et al., “Adiponectin inhibits Toll-like receptor family-induced signaling,” FEBS Letters, vol. 579, no. 30, pp. 6821–6826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Neumeier, J. Weigert, A. Schaffler et al., “Different effects of adiponectin isoforms in human monocytic cells,” Journal of Leukocyte Biology, vol. 79, no. 4, pp. 803–808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473–2476, 1999. View at Publisher · View at Google Scholar
  9. T. Zhao, M. Hou, M. Xia et al., “Globular adiponectin decreases leptin-induced tumor necrosis factor-α expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways,” Cellular Immunology, vol. 238, no. 1, pp. 19–30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Gainsford, T. A. Willson, D. Metcalf et al., “Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14564–14568, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. A. La Cava and G. Matarese, “The weight of leptin in immunity,” Nature Reviews Immunology, vol. 4, no. 5, pp. 371–379, 2004. View at Publisher · View at Google Scholar
  12. Z. Tian, R. Sun, H. Wei, and B. Gao, “Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation,” Biochemical and Biophysical Research Communications, vol. 298, no. 3, pp. 297–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar
  14. C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Hirosumi, G. Tuncman, L. Chang et al., “A central role for JNK in obesity and insulin resistance,” Nature, vol. 420, no. 6913, pp. 333–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. H. Lee, J. Giraud, R. J. Davis, and M. F. White, “c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2896–2902, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Ozcan, Q. Cao, E. Yilmaz et al., “Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes,” Science, vol. 306, no. 5695, pp. 457–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Merial, A. Bouloumie, V. Trocheris, M. Lafontan, and J. Galitzky, “Nitric oxide-dependent downregulation of adipocyte UCP-2 expression by tumor necrosis factor-α,” American Journal of Physiology - Cell Physiology, vol. 279, no. 4, pp. C1100–C1106, 2000. View at Google Scholar
  20. S. Kaser, A. Kaser, A. Sandhofer, C. F. Ebenbichler, H. Tilg, and J. R. Patsch, “Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro,” Biochemical and Biophysical Research Communications, vol. 309, no. 2, pp. 286–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh, and N. Z. Ehtesham, “Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1092–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Verma, S. H. Li, C. H. Wang et al., “Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction,” Circulation, vol. 108, no. 6, pp. 736–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Takahashi, S. Mizuarai, H. Araki et al., “Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46654–46660, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Shah, C. C. Hinkle, J. F. Ferguson et al., “Fractalkine is a novel human adipochemokine associated with type 2 diabetes,” Diabetes, vol. 60, no. 5, pp. 1512–1518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. C. Alessi, M. Poggi, and I. Juhan-Vague, “Plasminogen activator inhibitor-1, adipose tissue and insulin resistance,” Current Opinion in Lipidology, vol. 18, no. 3, pp. 240–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. L. Correia and W. G. Haynes, “A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2183–2185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Skurk and H. Hauner, “Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1,” International Journal of Obesity, vol. 28, no. 11, pp. 1357–1364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Liang, T. Kanjanabuch, S. L. Mao et al., “Plasminogen activator inhibitor-1 modulates adipocyte differentiation,” American Journal of Physiology - Endocrinology and Metabolism, vol. 290, no. 1, pp. E103–E113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. C. Chang, T. J. Chang, W. J. Lee, and L. M. Chuang, “The relationship of visfatin/pre–B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids,” Metabolism, vol. 59, no. 1, pp. 93–99, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Visfatin: a protein secreted by visceral fat that mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Sengenes, M. Berlan, I. De Glisezinski, M. Lafontan, and J. Galitzky, “Natriuretic peptides: a new lipolytic pathway in human adipocytes,” The FASEB Journal, vol. 14, no. 10, pp. 1345–1351, 2000. View at Publisher · View at Google Scholar
  32. A. Gomes, G. Correia, M. Coelho et al., “Dietary unsaturated fatty acids differently affect catecholamine handling by adrenal chromaffin cells,” The Journal of Nutritional Biochemistry, vol. 26, no. 5, pp. 563–570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Lafontan and D. Langin, “Lipolysis and lipid mobilization in human adipose tissue,” Progress in Lipid Research, vol. 48, no. 5, pp. 275–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Moro, F. Crampes, C. Sengenes et al., “Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans,” The FASEB Journal, vol. 18, no. 7, pp. 908–910, 2004. View at Publisher · View at Google Scholar
  35. T. Tsiloulis and M. J. Watt, “Chapter eight - exercise and the regulation of adipose tissue metabolism,” Progress in Molecular Biology and Translational Science, vol. 135, pp. 175–201, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Tsoli, M. M. Swarbrick, and G. R. Robertson, “Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia,” Seminars in Cell & Developmental Biology, vol. 54, pp. 68–81, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Arner and D. Langin, “Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance,” Trends in Endocrinology & Metabolism, vol. 25, no. 5, pp. 255–262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Krintel, M. Morgelin, D. T. Logan, and C. Holm, “Phosphorylation of hormone-sensitive lipase by protein kinase A in vitro promotes an increase in its hydrophobic surface area,” The FEBS Journal, vol. 276, no. 17, pp. 4752–4762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Morigny, M. Houssier, E. Mouisel, and D. Langin, “Adipocyte lipolysis and insulin resistance,” Biochimie, vol. 125, pp. 259–266, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Huss and D. P. Kelly, “Nuclear receptor signaling and cardiac energetics,” Circulation Research, vol. 95, no. 6, pp. 568–578, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. J. Chapman, “Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease,” Pharmacology & Therapeutics, vol. 111, no. 3, pp. 893–908, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. B. A. Fielding and K. N. Frayn, “Lipoprotein lipase and the disposition of dietary fatty acids,” The British Journal of Nutrition, vol. 80, no. 6, pp. 495–502, 1998. View at Publisher · View at Google Scholar
  43. S. Kersten, “Physiological regulation of lipoprotein lipase,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1841, no. 7, pp. 919–933, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. C. A. Harris, J. T. Haas, R. S. Streeper et al., “DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes,” Journal of Lipid Research, vol. 52, no. 4, pp. 657–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Assimacopoulos-Jeannet, S. Brichard, F. Rencurel, I. Cusin, and B. Jeanrenaud, “In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues,” Metabolism, vol. 44, no. 2, pp. 228–233, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Su and N. A. Abumrad, “Cellular fatty acid uptake: a pathway under construction,” Trends in Endocrinology & Metabolism, vol. 20, no. 2, pp. 72–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. B. Kim and B. M. Spiegelman, “ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism,” Genes & Development, vol. 10, no. 9, pp. 1096–1107, 1996. View at Publisher · View at Google Scholar
  48. W. J. Roesler, E. A. Park, and P. J. McFie, “Characterization of CCAAT/enhancer-binding protein α as a cyclic AMP-responsive nuclear regulator,” The Journal of Biological Chemistry, vol. 273, no. 24, pp. 14950–14957, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. E. D. Rosen, C. J. Walkey, P. Puigserver, and B. M. Spiegelman, “Transcriptional regulation of adipogenesis,” Genes & Development, vol. 14, no. 11, pp. 1293–1307, 2000. View at Publisher · View at Google Scholar
  50. L. Guo, X. Li, and Q. Q. Tang, “Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) β,” The Journal of Biological Chemistry, vol. 290, no. 2, pp. 755–761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. M. S. Alvarez, A. Fernandez-Alvarez, C. Cucarella, and M. Casado, “Stable SREBP-1a knockdown decreases the cell proliferation rate in human preadipocyte cells without inducing senescence,” Biochemical and Biophysical Research Communications, vol. 447, no. 1, pp. 51–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. J. D. Brunzell and R. A. Failor, “Diagnosis and treatment of dyslipidemia,” ACP Medicine, vol. 1, pp. 1–23, 2006. View at Google Scholar
  53. P. S. Jellinger, Y. Handelsman, P. D. Rosenblit et al., “American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis,” Endocrine Practice, vol. 23, Supplement 2, 2017. View at Publisher · View at Google Scholar
  54. C. A. Curat, A. Miranville, C. Sengenes et al., “From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes,” Diabetes, vol. 53, no. 5, pp. 1285–1292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Ng, T. Fleming, M. Robinson et al., “Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013,” Lancet, vol. 384, no. 9945, pp. 766–781, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. R. E. Heinl, D. S. Dhindsa, E. N. Mahlof et al., “Comprehensive cardiovascular risk reduction and cardiac rehabilitation in diabetes and the metabolic syndrome,” Canadian Journal of Cardiology, vol. 32, no. 10, pp. S349–S357, 2016. View at Publisher · View at Google Scholar
  57. J. D. Cohen, M. J. Cziraky, Q. Cai et al., “30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006,” The American Journal of Cardiology, vol. 106, no. 7, pp. 969–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Lamon-Fava, P. W. F. Wilson, and E. J. Schaefer, “Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 12, pp. 1509–1515, 1996. View at Publisher · View at Google Scholar
  59. K. Fon Tacer and D. Rozman, “Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation,” Journal of Lipids, vol. 2011, Article ID 783976, 14 pages, 2011. View at Publisher · View at Google Scholar
  60. K. Bencharif, L. Hoareau, R. K. Murumalla et al., “Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes,” Lipids in Health and Disease, vol. 9, p. 75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Krautbauer, M. Neumeier, K. Eisinger et al., “LDL but not HDL increases adiponectin release of primary human adipocytes,” Experimental and Molecular Pathology, vol. 95, no. 3, pp. 325–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Ishihara, K. Ohmori, M. Mizukawa, A. U. Hasan, T. Noma, and M. Kohno, “Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice,” Atherosclerosis, vol. 212, no. 1, pp. 131–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. N. Alexopoulos, B. H. Melek, C. D. Arepalli et al., “Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (beyond endorsed lipid lowering with EBT scanning),” Journal of the American College of Cardiology, vol. 61, no. 19, pp. 1956–1961, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Bey, P. Maigret, H. Laouenan, and M. T. Hamilton, “Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug,” Pharmacology, vol. 66, no. 1, pp. 51–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Saiki, Y. Miyashita, and K. Shirai, “The role of pitavastatin-enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes,” Journal of Atherosclerosis and Thrombosis, vol. 13, no. 2, p. 122, 2006. View at Publisher · View at Google Scholar
  66. C. Song, Z. Guo, Q. Ma et al., “Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells,” Biochemical and Biophysical Research Communications, vol. 308, no. 3, pp. 458–462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Labuzek, L. Buldak, A. Dulawa-Buldak et al., “Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia,” Pharmacological Reports, vol. 63, no. 5, pp. 1124–1136, 2011. View at Publisher · View at Google Scholar
  68. R. Krysiak, W. Zmuda, and B. Okopien, “The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: a preliminary report,” Pharmacological Reports, vol. 66, no. 5, pp. 880–884, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Maeda and N. Horiuchi, “Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP–PKA pathway induced by inhibition of protein prenylation,” Journal of Biochemistry, vol. 145, no. 6, pp. 771–781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. P. Zhao and Z. H. Wu, “Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits,” Clinica Chimica Acta, vol. 360, no. 1-2, pp. 133–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Krysiak, W. Zmuda, and B. Okopien, “The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia,” Cardiovascular Therapeutics, vol. 32, no. 2, pp. 40–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Ichida, G. Hasegawa, M. Fukui et al., “Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes,” Pharmacology, vol. 76, no. 1, pp. 34–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Li, L. Z. Chen, S. P. Zhao, and X. S. Huang, “Inflammation activation contributes to adipokine imbalance in patients with acute coronary syndrome,” PLoS One, vol. 11, no. 3, article e0151916, 2016. View at Publisher · View at Google Scholar
  74. S.-P. Zhao and D.-Q. Zhang, “Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits,” Clinica Chimica Acta, vol. 336, pp. 103–108, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Dobashi, S. Araki, K. Kubo, R. Kawagoe, Y. Yamamoto, and A. Shirahata, “Hydroxymethylglutaryl–CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3–L1 preadipocytes,” Life Sciences, vol. 82, no. 1-2, pp. 85–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. X. Yin, L. Tu, and H. Yang, “Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes,” Journal of Huazhong University of Science and Technology, vol. 27, no. 3, pp. 248–251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Wang, Y. Lin, N. Luo et al., “Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits,” Chinese Medical Journal, vol. 127, no. 16, pp. 2953–2959, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Abe, M. Matsuda, H. Kobayashi et al., “Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-β pathway in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 871–877, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Laumen, T. Skurk, and H. Hauner, “The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes,” Atherosclerosis, vol. 196, no. 2, pp. 565–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. M. Lobo, B. M. Quinto, L. Oyama et al., “TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes,” Cytokine, vol. 60, no. 1, pp. 150–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Sakamoto, M. Osaki, A. Hozumi et al., “Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes,” BMC Musculoskeletal Disorders, vol. 12, no. 1, p. 82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. Z. H. Wu, Y. Q. Chen, and S. P. Zhao, “Simvastatin inhibits ox-LDL-induced inflammatory adipokines secretion via amelioration of ER stress in 3T3-L1 adipocyte,” Biochemical and Biophysical Research Communications, vol. 432, no. 2, pp. 365–369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Takagi, M. Matsuda, M. Abe et al., “Effect of pravastatin on the development of diabetes and adiponectin production,” Atherosclerosis, vol. 196, no. 1, pp. 114–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Busnelli, S. Manzini, A. Froio et al., “Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury – rescue by high-dose statin treatment,” PLoS One, vol. 8, no. 11, article e80588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Araki, K. Dobashi, K. Asayama, and A. Shirahata, “Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes,” Free Radical Research, vol. 41, no. 9, pp. 1028–1034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. R. B. Singh, S. A. Mengi, Y. J. Xu, A. S. Arneja, and N. S. Dhalla, “Pathogenesis of atherosclerosis: A multifactorial process,” Experimental & Clinical Cardiology, vol. 7, no. 1, pp. 40–53, 2002. View at Google Scholar
  87. R. Ross and L. Agius, “The process of atherogenesis — cellular and molecular interaction: from experimental animal models to humans,” Diabetologia, vol. 35, Supplement 2, pp. S34–S40, 1992. View at Publisher · View at Google Scholar · View at Scopus
  88. S. P. Zhao and D. Q. Zhang, “Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits,” Clinica Chimica Acta, vol. 339, no. 1-2, pp. 189–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. M. R. Breen, M. Camps, F. Carvalho-Simoes, A. Zorzano, and P. F. Pilch, “Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion,” PLoS One, vol. 7, no. 4, article e34516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. S. P. Zhao, Z. H. Wu, S. C. Hong, H. J. Ye, and J. Wu, “Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits,” Clinica Chimica Acta, vol. 365, pp. 119–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. A. W. Cohen, B. Razani, X. B. Wang et al., “Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue,” American Journal of Physiology - Cell Physiology, vol. 285, no. 1, pp. C222–C235, 2003. View at Publisher · View at Google Scholar
  92. L. Liu, D. Brown, M. McKee et al., “Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance,” Cell Metabolism, vol. 8, no. 4, pp. 310–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. J. H. Chidlow Jr. and W. C. Sessa, “Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation,” Cardiovascular Research, vol. 86, no. 2, pp. 219–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Nowis, A. Malenda, K. Furs et al., “Statins impair glucose uptake in human cells,” BMJ Open Diabetes Research & Care, vol. 2, no. 1, article e000017, 2014. View at Publisher · View at Google Scholar
  95. S. Ganesan and M. K. Ito, “Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes,” Metabolic Syndrome and Related Disorders, vol. 11, no. 4, pp. 251–255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Takaguri, K. Satoh, M. Itagaki, Y. Tokumitsu, and K. Ichihara, “Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes,” Journal of Pharmacological Sciences, vol. 107, no. 1, pp. 80–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. C. Poletto, A. David-Silva, A. P. Yamamoto, U. F. Machado, and D. T. Furuya, “Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment,” Diabetology & Metabolic Syndrome, vol. 7, p. 18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. N. de las Heras, M. Valero-Munoz, S. Ballesteros et al., “Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 23, no. 11, pp. 1107–1114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Valero-Munoz, B. Martin-Fernandez, S. Ballesteros, V. Cachofeiro, V. Lahera, and N. de Las Heras, “Rosuvastatin improves insulin sensitivity in overweight rats induced by high fat diet. Role of SIRT1 in adipose tissue,” Clínica e Investigación en Arteriosclerosis, vol. 26, no. 4, pp. 161–167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. V. A. Salunkhe, I. G. Mollet, J. K. Ofori et al., “Dual effect of rosuvastatin on glucose homeostasis through improved insulin sensitivity and reduced insulin secretion,” eBioMedicine, vol. 10, pp. 185–194, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. Z. Zhang, S. Li, M. Cui et al., “Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways,” Basic Research in Cardiology, vol. 108, no. 2, p. 333, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Pengde, P. Fuxing, S. Bin, Y. Jing, and C. Jingqiu, “Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits,” Joint, Bone, Spine, vol. 75, no. 6, pp. 696–701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Elfakhani, S. Torabi, D. Hussein, N. Mills, G. F. Verbeck, and H. Mo, “Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes,” Experimental Biology and Medicine, vol. 239, no. 3, pp. 293–301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. W. Yi and X. Xu, “Mevastatin inhibits the differentiation of thyroid-associated ophthalmopathy derived orbital preadipocytes,” Zhong Nan Da Xue Xue Bao. Yi Xue Ban, vol. 35, no. 5, pp. 511–517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Tomiyama, E. Nishio, and Y. Watanabe, “Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation,” Japanese Journal of Pharmacology, vol. 80, no. 4, pp. 375–378, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. L. H. Chamberlain, “Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes,” FEBS Letters, vol. 507, no. 3, pp. 357–361, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. T. Khan, M. P. Hamilton, D. I. Mundy, S. C. Chua, and P. E. Scherer, “Impact of simvastatin on adipose tissue: pleiotropic effects in vivo,” Endocrinology, vol. 150, no. 12, pp. 5262–5272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. B. W. Phillips, N. Belmonte, C. Vernochet, G. Ailhaud, and C. Dani, “Compactin enhances osteogenesis in murine embryonic stem cells,” Biochemical and Biophysical Research Communications, vol. 284, no. 2, pp. 478–484, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998. View at Publisher · View at Google Scholar
  110. M. Rosenson, “Lipid lowering with fibric acid derivatives,” UpToDate, M. Freeman, Ed., UpToDate, Waltham, MA, USA, 2017. View at Google Scholar
  111. G. Derosa, A. Sahebkar, and P. Maffioli, “The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice,” Journal of Cellular Physiology, vol. 233, no. 1, pp. 153–161, 2017. View at Publisher · View at Google Scholar
  112. F. Yan, Q. Wang, C. Xu et al., “Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect,” PLoS One, vol. 9, no. 6, article e99245, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Cabrero, M. Alegret, R. M. Sanchez, T. Adzet, J. C. Laguna, and M. Vazquez, “Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes,” Diabetes, vol. 50, no. 8, pp. 1883–1890, 2001. View at Publisher · View at Google Scholar
  114. M. Vazquez, N. Roglans, A. Cabrero et al., “Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal β-oxidation in rat white adipose tissue,” Molecular and Cellular Biochemistry, vol. 216, no. 1-2, pp. 71–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  115. T. Goto, J. Y. Lee, A. Teraminami et al., “Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes,” Journal of Lipid Research, vol. 52, no. 5, pp. 873–884, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Baldo, A. D. Sniderman, and K. Cianflone, “Increase in intracellular triglyceride synthesis induced by gemfibrozil,” Metabolism, vol. 43, no. 2, pp. 257–262, 1994. View at Publisher · View at Google Scholar · View at Scopus
  117. T. L. Rachid, A. Penna-de-Carvalho, I. Bringhenti, M. B. Aguila, C. A. Mandarim-de-Lacerda, and V. Souza-Mello, “PPAR-α agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice,” Cell Biochemistry & Function, vol. 33, no. 4, pp. 249–256, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. M. C. Gonzalez, H. Vidal, E. Herrera, and C. Bocos, “Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms,” BMB Reports, vol. 42, no. 10, pp. 679–684, 2009. View at Publisher · View at Google Scholar
  119. A. V. Ferreira, Z. Menezes-Garcia, E. G. Mario, H. L. Delpuerto, A. S. Martins, and L. M. Botion, “Increased expression of oxidative enzymes in adipose tissue following PPARα-activation,” Metabolism, vol. 63, no. 4, pp. 456–460, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. T. L. Rachid, A. Penna-de-Carvalho, I. Bringhenti, M. B. Aguila, C. A. Mandarim-de-Lacerda, and V. Souza-Mello, “Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice,” Molecular and Cellular Endocrinology, vol. 402, pp. 86–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. A. V. Ferreira, G. G. Parreira, A. Green, and L. M. Botion, “Effects of fenofibrate on lipid metabolism in adipose tissue of rats,” Metabolism, vol. 55, no. 6, pp. 731–735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. R. Brandes, R. Arad, and J. Bar-Tana, “Adipose conversion of cultured rat primary preadipocytes by hypolipidemic drugs,” Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol. 877, no. 2, pp. 314–321, 1986. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Sedova, O. Seda, D. Krenova, V. Kren, and L. Kazdova, “Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome,” International Journal of Obesity and Related Metabolic Disorders, vol. 28, no. 5, pp. 719–725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Chen, D. Deng, Z. Fang et al., “Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue,” Endocrine, vol. 45, no. 3, pp. 409–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Jeong and M. Yoon, “Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARα in high fat diet-induced obese mice,” Experimental & Molecular Medicine, vol. 41, no. 6, pp. 397–405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. K. Oki, J. Koide, S. Nakanishi, R. Nakashima, and K. Yamane, “Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia,” Endocrine Journal, vol. 54, no. 3, pp. 431–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Toyoda, Y. Kamei, H. Kato et al., “Effect of peroxisome proliferator-activated receptor-α ligands in the interaction between adipocytes and macrophages in obese adipose tissue,” Obesity, vol. 16, no. 6, pp. 1199–1207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. S. P. Zhao and J. Wu, “Fenofibrate reduces tumor necrosis factor-α serum concentration and adipocyte secretion of hypercholesterolemic rabbits,” Clinica Chimica Acta, vol. 347, no. 1-2, pp. 145–150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Bauer, J. Weigert, M. Neumeier et al., “Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals,” Archives of Medical Research, vol. 41, no. 2, pp. 75–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Nakano, Y. Inada, H. Masuzaki et al., “Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes,” American Journal of Physiology - Endocrinology and Metabolism, vol. 292, no. 4, pp. E1213–E1222, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Hiuge, A. Tenenbaum, N. Maeda et al., “Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 635–641, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. W. Wang, Q. Lin, R. Lin et al., “PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway,” Experimental Cell Research, vol. 319, no. 10, pp. 1523–1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Weigert, M. Neumeier, S. Bauer et al., “Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release,” FEBS Letters, vol. 582, no. 19, pp. 2965–2972, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. S. P. Zhao, J. Wu, D. Q. Zhang, H. J. Ye, L. Liu, and J. Q. Li, “Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit,” Atherosclerosis, vol. 177, no. 2, pp. 255–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Glorian, S. Franckhauser-Vogel, D. Robin, P. Robin, and C. Forest, “Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes,” Journal of Cellular Biochemistry, vol. 68, no. 3, pp. 298–308, 1998. View at Publisher · View at Google Scholar
  136. P. Verrando, R. Negrel, P. Grimaldi, M. Murphy, and G. Ailhaud, “Differentiation of ob 17 preadipocytes to adipocytes triggering effects of clofenapate and indomethacin,” Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol. 663, no. 1, pp. 255–265, 1981. View at Publisher · View at Google Scholar · View at Scopus
  137. D. Pasquali, G. M. Pierantoni, A. Fusco et al., “Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves’ ophthalmopathy,” Journal of Molecular Endocrinology, vol. 33, no. 1, pp. 133–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Garg, A. Sharma, P. Krishnamoorthy et al., “Role of niacin in current clinical practice: a systematic review,” The American Journal of Medicine, vol. 130, no. 2, pp. 173–187, 2017. View at Publisher · View at Google Scholar · View at Scopus
  139. V. S. Kamanna and M. L. Kashyap, “Mechanism of action of niacin,” The American Journal of Cardiology, vol. 101, no. 8A, pp. 20B–26B, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. S. P. Zhao, J. Yang, J. Li, S. Z. Dong, and Z. H. Wu, “Effect of niacin on LXRα and PPARγ expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits,” International Journal of Cardiology, vol. 124, no. 2, pp. 172–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. J. L. Probstfield and D. B. Hunninghake, “Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician,” Archives of Internal Medicine, vol. 154, no. 14, pp. 1557–1559, 1994. View at Publisher · View at Google Scholar
  142. J. A. Etchason, T. D. Miller, R. W. Squires et al., “Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin,” Mayo Clinic Proceedings, vol. 66, no. 1, pp. 23–28, 1991. View at Publisher · View at Google Scholar
  143. F. Karpe and K. N. Frayn, “The nicotinic acid receptor–a new mechanism for an old drug,” Lancet, vol. 363, no. 9424, pp. 1892–1894, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Zhang, R. J. Schmidt, P. Foxworthy et al., “Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A,” Biochemical and Biophysical Research Communications, vol. 334, no. 2, pp. 729–732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  145. E. P. Plaisance, M. Lukasova, S. Offermanns, Y. Zhang, G. Cao, and R. L. Judd, “Niacin stimulates adiponectin secretion through the GPR109A receptor,” American Journal of Physiology - Endocrinology and Metabolism, vol. 296, no. 3, pp. E549–E558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. L. A. Carlson, “Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro,” Acta Medica Scandinavica, vol. 173, pp. 719–722, 1963. View at Publisher · View at Google Scholar · View at Scopus
  147. Y. T. Oh, K. S. Oh, Y. M. Choi et al., “Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue,” American Journal of Physiology - Endocrinology and Metabolism, vol. 300, no. 6, pp. E1012–E1021, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. M. M. Heemskerk, S. A. van den Berg, A. C. Pronk et al., “Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B,” American Journal of Physiology - Endocrinology and Metabolism, vol. 306, no. 7, pp. E808–E813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  149. M. M. Heemskerk, H. K. Dharuri, S. A. van den Berg et al., “Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile,” Journal of Lipid Research, vol. 55, no. 12, pp. 2532–2540, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. J. E. Digby, E. McNeill, O. J. Dyar, V. Lam, D. R. Greaves, and R. P. Choudhury, “Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin,” Atherosclerosis, vol. 209, no. 1, pp. 89–95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Westphal, K. Borucki, E. Taneva, R. Makarova, and C. Luley, “Extended-release niacin raises adiponectin and leptin,” Atherosclerosis, vol. 193, no. 2, pp. 361–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. Z. H. Wu and S. P. Zhao, “Niacin promotes cholesterol efflux through stimulation of the PPARγ-LXRα-ABCA1 pathway in 3T3-L1 adipocytes,” Pharmacology, vol. 84, no. 5, pp. 282–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. H. J. Knowles, R. H. te Poele, P. Workman, and A. L. Harris, “Niacin induces PPARγ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways,” Biochemical Pharmacology, vol. 71, no. 5, pp. 646–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  154. K. Fujimori and F. Amano, “Niacin promotes adipogenesis by reducing production of anti-adipogenic PGF2α through suppression of C/EBPβ-activated COX-2 expression,” Prostaglandins & Other Lipid Mediators, vol. 94, no. 3-4, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. H. Takase, Y. Dohi, T. Okado, T. Hashimoto, Y. Goto, and G. Kimura, “Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study,” European Journal of Clinical Investigation, vol. 42, no. 12, pp. 1287–1294, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. R. Krysiak, W. Zmuda, and B. Okopien, “The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia,” Pharmacological Reports, vol. 66, no. 3, pp. 442–447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. R. Krysiak, W. Zmuda, B. Marek, and B. Okopien, “The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia,” Endokrynologia Polska, vol. 65, no. 4, pp. 275–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  158. A. M. Heck, J. A. Yanovski, and K. A. Calis, “Orlistat, a new lipase inhibitor for the management of obesity,” Pharmacotherapy, vol. 20, no. 3, pp. 270–279, 2000. View at Publisher · View at Google Scholar
  159. M. Beg, K. Shankar, S. Varshney et al., “A clerodane diterpene inhibit adipogenesis by cell cycle arrest and ameliorate obesity in C57BL/6 mice,” Molecular and Cellular Endocrinology, vol. 399, pp. 373–385, 2015. View at Publisher · View at Google Scholar · View at Scopus
  160. D. Kim, J. H. Park, D. J. Kweon, and G. D. Han, “Bioavailability of nanoemulsified conjugated linoleic acid for an antiobesity effect,” International Journal of Nanomedicine, vol. 8, pp. 451–459, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. M. S. Gauthier, H. Miyoshi, S. C. Souza et al., “AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance,” The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16514–16524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Bougoulia, A. Triantos, and G. Koliakos, “Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women,” Hormones, vol. 5, no. 4, pp. 259–269, 2006. View at Publisher · View at Google Scholar
  163. C. J. Hsieh, P. W. Wang, R. T. Liu et al., “Orlistat for obesity: benefits beyond weight loss,” Diabetes Research and Clinical Practice, vol. 67, no. 1, pp. 78–83, 2005. View at Publisher · View at Google Scholar · View at Scopus
  164. G. Valsamakis, P. G. McTernan, R. Chetty et al., “Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines,” Metabolism, vol. 53, no. 4, pp. 430–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. H. Yu, R. B. Rothman, C. M. Dersch, J. S. Partilla, and K. C. Rice, “Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters,” Bioorganic & Medicinal Chemistry, vol. 8, no. 12, pp. 2689–2692, 2000. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Dobrzanski and N. S. Doggett, “The effect of propranolol phentolamine and pimozide on drug-induced anorexia in the mouse,” Psychopharmacology, vol. 66, no. 3, pp. 297–300, 1979. View at Publisher · View at Google Scholar · View at Scopus
  167. H. E. Bays, “Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease,” Expert Review of Cardiovascular Therapy, vol. 7, no. 11, pp. 1429–1445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. H. E. Bays, “Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development,” Expert Review of Cardiovascular Therapy, vol. 9, no. 3, pp. 265–277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. J. R. Clapper, J. Athanacio, C. Wittmer et al., “Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 292–298, 2013. View at Publisher · View at Google Scholar · View at Scopus
  170. S. R. Smith, K. Fujioka, A. K. Gupta et al., “Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity,” Diabetes, Obesity and Metabolism, vol. 15, no. 9, pp. 863–866, 2013. View at Publisher · View at Google Scholar · View at Scopus
  171. D. M. Abo-Elmatty and S. A. Zaitone, “Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 10, pp. 1187–1195, 2011. View at Google Scholar
  172. D. A. York, L. Singer, S. Thomas, and G. A. Bray, “Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs,” Nutrition, vol. 16, no. 10, pp. 967–975, 2000. View at Publisher · View at Google Scholar · View at Scopus
  173. T. J. Kieffer and J. F. Habener, “The glucagon-like peptides,” Endocrine Reviews, vol. 20, no. 6, pp. 876–913, 1999. View at Publisher · View at Google Scholar
  174. J. J. Holst, C. Orskov, O. V. Nielsen, and T. W. Schwartz, “Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut,” FEBS Letters, vol. 211, no. 2, pp. 169–174, 1987. View at Publisher · View at Google Scholar · View at Scopus
  175. K. Inoue, N. Maeda, S. Kashine et al., “Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes,” Cardiovascular Diabetology, vol. 10, p. 109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. Y. Shao, G. Yuan, J. Zhang, and X. Guo, “Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression,” Drug Design, Development and Therapy, vol. 9, pp. 1177–1184, 2015. View at Publisher · View at Google Scholar · View at Scopus
  177. M. Jensterle, T. Kocjan, N. A. Kravos, M. Pfeifer, and A. Janez, “Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome,” Endocrine Research, vol. 40, no. 3, pp. 133–138, 2015. View at Publisher · View at Google Scholar · View at Scopus
  178. V. Hoang, J. Bi, S. M. Mohankumar, and A. K. Vyas, “Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome,” PLoS One, vol. 10, no. 5, article e0126119, 2015. View at Publisher · View at Google Scholar · View at Scopus
  179. K. Nonogaki, M. Hazama, and N. Satoh, “Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice,” BioMed Research International, vol. 2014, Article ID 751930, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  180. K. M. Heppner, S. Marks, J. Holland et al., “Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice,” Diabetologia, vol. 58, no. 9, pp. 2124–2132, 2015. View at Publisher · View at Google Scholar · View at Scopus
  181. R. El Bekay, L. Coin-Araguez, D. Fernandez-Garcia et al., “Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes,” British Journal of Pharmacology, vol. 173, no. 11, pp. 1820–1834, 2016. View at Publisher · View at Google Scholar · View at Scopus
  182. C. J. Li, Q. Yu, P. Yu et al., “Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients,” Cardiovascular Diabetology, vol. 13, p. 36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  183. A. Tang, R. Rabasa-Lhoret, H. Castel et al., “Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial,” Diabetes Care, vol. 38, no. 7, pp. 1339–1346, 2015. View at Publisher · View at Google Scholar · View at Scopus
  184. D. Suzuki, M. Toyoda, M. Kimura et al., “Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus,” Internal Medicine, vol. 52, no. 10, pp. 1029–1034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  185. M. Yang, L. Zhang, C. Wang et al., “Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance,” PLoS One, vol. 7, no. 11, article e48392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  186. J. Jendle, M. A. Nauck, D. R. Matthews et al., “Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue,” Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1163–1172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. S. Morano, E. Romagnoli, T. Filardi et al., “Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study,” Acta Diabetologica, vol. 52, no. 4, pp. 727–732, 2015. View at Publisher · View at Google Scholar · View at Scopus
  188. D. Beiroa, M. Imbernon, R. Gallego et al., “GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK,” Diabetes, vol. 63, no. 10, pp. 3346–3358, 2014. View at Publisher · View at Google Scholar · View at Scopus
  189. G. Cantini, A. Di Franco, J. Samavat, G. Forti, E. Mannucci, and M. Luconi, “Effect of liraglutide on proliferation and differentiation of human adipose stem cells,” Molecular and Cellular Endocrinology, vol. 402, pp. 43–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  190. L. Bai, Y. Wang, J. Fan et al., “Dissecting multiple steps of GLUT4 trafficking and identifying the sites of insulin action,” Cell Metabolism, vol. 5, no. 1, pp. 47–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  191. R. Z. Yang, M. J. Lee, H. Hu et al., “Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action,” American Journal of Physiology - Endocrinology and Metabolism, vol. 290, no. 6, pp. E1253–E1261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  192. P. Yan, L. Li, M. Yang et al., “Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 92, no. 3, pp. 368–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. D. J. Cuthbertson, A. Irwin, C. J. Gardner et al., “Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists,” PLoS One, vol. 7, no. 12, article e50117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  194. T. D. Challa, N. Beaton, M. Arnold, G. Rudofsky, W. Langhans, and C. Wolfrum, “Regulation of adipocyte formation by GLP-1/GLP-1R signaling,” The Journal of Biological Chemistry, vol. 287, no. 9, pp. 6421–6430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  195. B. D. Henriksbo, T. C. Lau, J. F. Cavallari et al., “Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance,” Diabetes, vol. 63, no. 11, pp. 3742–3747, 2014. View at Publisher · View at Google Scholar · View at Scopus
  196. L. Aguirre, E. Hijona, M. T. Macarulla et al., “Several statins increase body and liver fat accumulation in a model of metabolic syndrome,” Journal of Physiology and Pharmacology, vol. 64, no. 3, pp. 281–288, 2013. View at Google Scholar
  197. M. Yang, R. Liu, S. Li et al., “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes,” Diabetes Care, vol. 36, no. 5, pp. 1074–1082, 2013. View at Publisher · View at Google Scholar · View at Scopus